Medical Health & Life Science Research News

Global anthrax pipeline therapeutics market review H2 2017 explored in latest research

The Anthrax pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease).

- Agency -.

New research report on Anthrax Pipeline Review, H2 2017 is added in ReportsnReports.com. The report provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Get Anthrax Pipeline Review, H2 2017 Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1132630 .

Anthrax is a serious infectious disease caused by Bacillus anthracis.

- Agency -.

Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing.

Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Companies are Altimmune Inc, Aphios Corp, Aradigm Corp, Companhia Industrial Produtora de Antibioticos SA, ContraFect Corp, Crestone Inc, Dynavax Technologies Corp, Emergent BioSolutions Inc, GlaxoSmithKline Plc, Green Cross Corp, Grifols SA, Hawaii Biotech Inc, iBio Inc,Merck & Co Inc,Microbiotix Inc, NanoBio Corp, PaxVax Inc, Pfenex Inc, Protein Potential LLC, ProThera Biologics Inc, Soligenix Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc, VLP Biotech Inc.

Access Complete Report On Anthrax Pipeline Review, H2 2017: http://www.reportsnreports.com/contacts/discount.aspx?name=1132630

Anthrax - Drug Profiles – anthrax vaccine, Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax, ARD-3100, AV-7909, BDM-I, CF-306, CF-307, CF-308, ciprofloxacin hydrochloride, CPN-1311, DPX-Anthrax, DV-230, epimerox, EV-035, GC-1109, gepotidacin mesylate, GREANX, KKL, Marinus, Monoclonal Antibody, Nasoshield, PBI-220, raxibacumab and more..

Anthrax Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 2 and 2 respectively.

Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anthrax pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.